UICC – AMGEN WHA79 side event: AI serving better patient outcomes

Artificial intelligence is becoming an increasingly important part of cancer care, with applications ranging from earlier and more accurate diagnosis to treatment planning, patient monitoring, and supportive care. When used effectively, AI has the potential to enhance clinical decision‑making, improve efficiency across health systems, and contribute to more personalised and people-centred care.

As AI technologies are adopted at scale, however, important questions arise around how these tools are designed, governed, and implemented, particularly for cancer care. IData quality, patient safety, transparency, bias, privacy, and accountability are critical issues that need to be considered, as AI‑enabled systems may directly influence clinical pathways and patient outcomes. Without appropriate safeguards, there is a risk that innovation could exacerbate existing inequities, including between high‑income settings and low‑ and middle‑income countries.

This side event, convened by UICC with the support of its partner Amgen, will explore how AI can be integrated into cancer care in ways that genuinely serve the needs of people living with cancer. It will bring together perspectives from clinicians, industry, civil society, and global health actors to examine real‑world examples of AI in practice, alongside the governance and assurance mechanisms needed to ensure these technologies are safe, ethical, and trustworthy.

By focusing on responsible deployment rather than technology alone, the event aims to contribute to broader World Health Assembly discussions on digital health and innovation.

This event is organised by: